Concordant association validates MGMT methylation and protein expression as favorable prognostic factors in glioma patients on alkylating chemotherapy (Temozolomide)

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation and its subsequent loss of protein expression has been identified to have a variable impact on clinical outcome of glioma patients indicated for chemotherapy with alkylating agents (Temozolomide). This study investigated methylatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Pandith, Arshad A., Qasim, Iqbal, Zahoor, Wani, Shah, Parveen, Bhat, Abdul R., Sanadhya, Dheera, Shah, Zafar A., Naikoo, Niyaz A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928198/
https://www.ncbi.nlm.nih.gov/pubmed/29712977
http://dx.doi.org/10.1038/s41598-018-25169-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928198/
https://www.ncbi.nlm.nih.gov/pubmed/29712977
http://dx.doi.org/10.1038/s41598-018-25169-2

Ejemplares similares